Analysis Life Sciences Thank You A closer look at CDER’s new 2024 guidance agenda
Agency IQ
FEBRUARY 12, 2024
Accelerated Approval of Drugs and Biologics Administrative/ Procedural New Civil Monetary Penalties for Failure to Meet Accelerated Post Marketing Requirements Administrative/ Procedural Carried over from previous guidance agenda Exclusivity for First Interchangeable Biosimilar Biological Products Administrative/ Procedural Carried over from previous (..)
Let's personalize your content